Biologics Pharma Innovation Programme Singapore (BioPIPS)

BioPIPS or the Biologics Pharma Innovation Programme Singapore aims to strengthen local biomanufacturing capabilities and transform Singapore’s biologics manufacturing facilities into agile factories of the future. It works through a consortium model consisting leading biopharma companies and Singapore’s public sector R&D agencies and universities. BioPIPS is modelled after PIPS.

Vision: Transform biologics manufacturing through the introduction of new technologies and products into Singapore’s manufacturing facilities. 


  • Leverage public sector R&D capabilities to address problem statements from local biologics manufacturing facilities to enhance manufacturing productivity and operational efficiency 
  • Transform the existing biologics manufacturing operations in Singapore so that the manufacturing sites are best-in-class within their respective manufacturing network and well positioned for the introduction of new products and novel manufacturing technologies
  • Leverage strong foundation through synergies in operations, resources, learning and collaboration of technologies with PIPS
BioPIPS intro

Consortium Members

Combined Consortium Logos BioPIPS

A consortium agreement was inked on 15 March 2024 between the Agency for Science, Technology and Research (A*STAR), National University of Singapore (NUS), Nanyang Technological University, Singapore (NTU Singapore), Singapore Institute of Technology (SIT) and 3 major pharmaceutical MNCs, i.e. BioNTech Pharmaceuticals Asia Pacific Pte Ltd, GlaxoSmithKline Biologicals and Sanofi Manufacturing Pte Ltd. They are also the founding Core Members of BioPIPS.

The Extended Team is a diverse group consisting pharmaceutical supply chain, technology, consultancy, training and engineering companies, including SMEs and LLEs invited by the Core Members to participate in specific projects. Interested companies are encouraged to contact the BioPIPS Programme Office to find out more about joining the consortium.

Note: Companies are listed in alphabetical order.

Signing Ceremony BioPIPS (800px)
BioNTech, GSK, Sanofi, NTU, NTUitive, NUS and SIT signed a membership agreement on 15 March 2024 to join the Biologics Pharma Innovation Programme Singapore (BioPIPS) consortium led by A*STAR and supported by EDB. EDB’s Cindy Koh, Executive Vice President and Member of EXCO, witnessed the membership agreement signing.


Sensing and Modelling
Focuses on developing and validating in-process, automated workflows to translate process performance into actionable knowledge. Specifically, the aim is to improve the accuracy and robustness of sensing technologies and facilitate the incorporation of AI and modelling approaches into manufacturing processes to enable quicker and more effective product and process control.
Sensing and Modelling (600px x 400px)

Focuses on technologies to achieve sustainability targets, including zero waste-to-landfill, and reducing environmental footprint and greenhouse gas emissions. The workstream aims to use models to identify sustainability bottlenecks in manufacturing and supply chains, explore new technologies to reduce resource utilisation and waste generation, and rethink the expanded utility of single-use equipment through the lens of materials science and circular economy considerations.
sustainable-(600px x 400px)

Compliant Agility
Underpinning medicine supply is the trust in the efficacy and safety of the manufactured products which need to comply to regulations. This workstream focuses on removing manual tasks to achieve greater productivity in the manufacturing facilities while maintaining compliance by using solutions, e.g. robotics, automation and advanced analytics. 
biorobots-concept (600px x 400px)

Media Releases

BioPIPS consortium in Singapore expands membership, seeks to enhance productivity and sustainability in biologics manufacturing, A*STAR Press Release

SINGAPORE – The Biologics Pharma Innovation Programme Singapore (BioPIPS) consortium has been expanded with the addition of global immunotherapy company, BioNTech. The company joins global pharmaceutical companies GSK and Sanofi alongside Singapore’s research organisations and institutes of higher learning Agency for Science, Technology and Research (A*STAR), Nanyang Technological University, Singapore (NTU) and its innovation and enterprise company, NTUitive, National University of Singapore (NUS), and Singapore Institute of Technology (SIT).

The BioPIPS consortium is led by A*STAR and supported by the Singapore Economic Development Board (EDB). It aims to grow Singapore’s capabilities in biologics manufacturing, focusing on increasing productivity and sustainability, to transform the existing base of biologics production in Singapore.

Get in touch with BioPIPS

Biologics Pharma Innovation Programme Singapore (BioPIPS) Programme Office
31 Biopolis Way
#08-01 Nanos
Singapore 138669

For all enquiries, contact us at We will get back to you as soon as we can.

Connect with us